CE Holdings (4320) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
10 Feb, 2026Executive summary
Achieved record-high revenue and profits in the first quarter, driven by major electronic medical record (EMR) system contract renewals despite a reduction in consolidated scope due to Micron's exclusion.
Net sales for the quarter ended December 31, 2025, rose 33.2% year-over-year to ¥5,057 million, with operating profit up 68.0% to ¥655 million and profit attributable to owners of parent up 87.3% to ¥376 million.
Earnings per share increased to ¥22.60 from ¥13.28 year-over-year.
Financial highlights
Revenue rose 33.2% year-over-year to ¥5,057 million in Q1.
Operating income increased 68.0% year-over-year to ¥655 million.
Ordinary income grew 68.4% year-over-year to ¥667 million.
Net income attributable to parent rose 87.3% year-over-year to ¥376 million.
Gross profit increased to ¥1,143.8 million from ¥913.3 million year-over-year, while operating profit rose to ¥655.5 million from ¥390.1 million.
Ordinary profit reached ¥667.2 million, up from ¥396.3 million year-over-year.
Comprehensive income attributable to owners of parent was ¥375.8 million, up from ¥200.7 million year-over-year.
Outlook and guidance
Full-year revenue forecast (excluding Micron) is ¥15,000 million, up 1.4% year-over-year.
Full-year net sales forecast for FY2026 is ¥15,000 million, a 5.3% decrease year-over-year.
Operating income projected at ¥1,500 million, up 4.5% year-over-year.
Operating profit for the full year is projected at ¥1,500 million, down 17.1% year-over-year.
Net income (excluding prior year’s one-time Micron share sale gain) expected to reach a record ¥870 million, up 16.5% year-over-year.
Profit attributable to owners of parent expected to decline 44.2% to ¥870 million.
Full-year EPS is forecast at ¥52.28.
No change from initial guidance.
Latest events from CE Holdings
- Record profit and revenue growth, but next year forecasts a decline in earnings.4320
Q4 202511 Nov 2025 - Revenue up 12% YoY, but profit fell over 20% and net loss posted due to impairments.4320
Q3 20248 Sep 2025 - Record revenue, but net income plunged on one-time losses; strong profit recovery forecast.4320
Q4 20248 Sep 2025 - Record Q1 profit and revenue growth, robust order intake, and higher dividend forecast.4320
Q1 20258 Sep 2025 - Record sales and profit growth, strong outlook, and higher dividends forecast.4320
Q2 20258 Sep 2025 - Record profit and revenue growth, with raised guidance and dividend forecast.4320
Q3 20258 Sep 2025